Docetaxel for patients with paclitaxel-resistant mullerian carcinoma

Journal of Clinical Oncology

Volumn 18, Issue 14, 2000, Pages 2733-2739

  Verschraegen, Claire F ^a   Sittisomwong, Tul ^a   Kudelka, Andrzej P ^a   de Paula Guedes, Ernesto ^a   Steger, Melissa ^a   Nelson Taylor, Tarra ^a   Vincent, Monique ^a   Rogers, Roger ^a   Atkinson, E Neely ^a   Kavanagh, John J ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HUMAN; MUELLERIAN DUCT; NEUROPATHY; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UTERINE TUBE CARCINOMA; VOMITING;

EID: 18244423415     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.14.2733     Document Type: Article

References (39)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
3. Markman M, Kennedy A, Webster K, et al: Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol 124:326-328, 1998
4. Eisenhauer EA, Vermorken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8:963-968, 1997
5. McGuire WP, Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol 25:340-348, 1998
6. Kudelka AP, Verschraegen CF, Shen Y, et al: Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. Int J Gynecol Cancer 9:44-53, 1999
7. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al: Long-term survival in ovarian cancer: Mature data from the Netherlands Joint Study Group For Ovarian Cancer. Eur J Cancer 27:1367-1372, 1991
8. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
9. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 32:2747-2755, 1993
10. Fromes Y, Gounon P, Veitia R, et al: Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem 15:377-388, 1996
11. Hanauske AR, Degen D, Hilsenbeck SG, et al: Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3:121-124, 1992
12. Untch M, Untch A, Sevin BU, et al: Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 5:24-30, 1994
13. Valero V, Jones SE, Von Hoff DD, et al: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362-3368, 1998
14. Aapro M, Pujade-Lauraine E, Lhomme C, et al: Phase II study of Taxotere (T) in ovarian cancer. EORTC Clinical Screening Group (CSG). Proc Am Soc Clin Oncol 12:256a, 1993 (abstr 809)
15. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
16. Kavanagh JJ, Kudelka AP, Gonzalez de Leon C, et al: Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2:837-842, 1996
17. Piccart MJ, Gore M, Ten Bokkel Huinink W, et al: Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676-681, 1995
18. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
19. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Breslow N: Comparison of survival curves, in Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials Methods and Practice. New York, NY, Oxford University Press, 1984
21. Holmes FA, Kudelka AP, Kavanagh JJ, et al: Current status of clinical trials with paclitaxel and docetaxel, in Georg GI, Chen TT, Ojima I, et al (eds): Taxane Anticancer Agents: Basic Science and Current Status. Washington, DC, American Chemical Society, 1995, pp 31-57
22. Adams M, Calvert AH, Carmichael J, et al: Chemotherapy for ovarian cancer: A consensus statement on standard practice. Br J Cancer 78:1404-1406, 1998
23. Berek JS, Bertelsen K, du Bois A, et al: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10:87-92, 1999
24. Sabbatini P, Spriggs D: Salvage therapy for ovarian cancer. Oncology (Huntingt) 12:833-843, 1998
25. Alberts DS: Treatment of refractory and recurrent ovarian cancer. Semin Oncol 26:8-14, 1999
26. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
27. Tresukosol D, Kudelka AP, Gonzales de Leon C, et al: Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynaecol Oncol 17:188-191, 1996
28. Riva A, Fumoleau P, Roche H: Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere (T). Proc Am Soc Clin Oncol 16:188a, 1997 (abstr 660)
29. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
30. Kudelka AP, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
31. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
32. Wils P, Phung-Ba V, Warnery A. et al: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528-1530, 1994
33. Horwitz SB, Cohen D, Rao S, et al: Taxol: Mechanisms of action and resistance. J Natl Cancer Inst Monogr 15:55-61, 1993
34. Haldar S, Basu A, Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233, 1997
35. Minotti AM, Barlow SB, Cabral F: Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987-3994, 1991
36. Kaye SB: Progress in the treatment of ovarian cancer: Scottish Gynaecological Cancer Trials Group. Anticancer Drugs 10:S29-S32. 1999 (suppl 1)
37. Benjapibal M, Kudelka AP, Vasuratna A, et al: Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. Anticancer Drugs 9:577-579, 1998
38. Khayat D, Antoine E: Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol 24:513-19-813-26, 1997 (suppl 13)
39. Vasey PA, Paul J, Birt A, et al: Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 17:2069-2080, 1999